Lilly-Lupin Bolster India Alliance But Cialis Faces Crowded Market
Executive Summary
Eli Lilly and Lupin are building on their alliance in India, with Lupin introducing Lilly’s Cialis (tadalafil) – a teeming market awaits the product, however.
You may also be interested in...
Deal Watch, Focus On Asia: Cipla Licenses India Rights To Lilly’s Basalgar
Cipla expands on its in-licensing strategy in India with Lilly’s insulin glargine product, while Aptose signs second agreement with CrystalGenomics to add Chinese rights for leukemia candidate CG-806, and Yakult gains Japanese rights to Verastem's duvelisib.
Lilly-Lupin link revs up Indian diabetes
A string of new marketing deals is set to redefine competition in the growing Indian diabetes market. The latest alliance involves Lilly and Lupin, where the Indian firm will promote and distribute Lilly's Huminsulin range in India and Nepal, doubling doctor reach for the insulin products to about 45,000 almost overnight.
First Cetuximab Biosimilar Debuts In India; Merck KGaA Sticks To Guns
Alkem’s ‘affordable’ cetuximab biosimilar set to take on Erbitux in India, even as Merck KGaA pursues a court case seeking information and data related to efficacy and interchangeability of the Indian company's product.